Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin, including the removal of actinic keratoses (AK’s ) — a precancerous skin condition caused by sun exposure. Fraxel re:store treatment provides superior results for AKs on the face or other areas of the body displaying the signs of photodamage.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/solta/45388/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
On June 5, CVS/pharmacy kicked-off its 10th annual in-store fundraising campaign -- “Researching a Cure” -- to support the fight against amyotrophic lateral sclerosis (ALS). Funds raised through the campaign benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research. Through the Researching a Cure campaign, CVS/pharmacy has raised more than $23 million in its stores and online at www.cvs.com, to fund new clinical research with the aim of discovering a treatment or cure for ALS. The 2011 campaign will run through June 25.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/50475/
Today, a new study from P&G Beauty & Grooming and lead investigator Nancy Etcoff, PhD., Assistant Clinical Professor at Harvard University and Associate Researcher at Massachusetts General Hospital Department of Psychiatry, confirms for the first time that using color cosmetics does, in fact, significantly alter how women are perceived by others, at first glance and over time. Results of the study, published on October 3, 2011 in PLoS ONE, show that makeup application specifically impacts judgments of attractiveness and character when viewed rapidly or for unlimited amounts of time.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52087-p-g-harvard-study-reveals-cosmetics-alter-instinctual-perception
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
Nestlé Health Science will unveil its pediatric closed system formulas with the new SpikeRight® PLUS port at the annual American Society for Parenteral and Enteral Nutrition’s (A.S.P.E.N.) Clinical Nutrition Week meeting being held in Orlando January 21-24. The introduction marks a significant step in supporting the provision of safe enteral (tube) feeding.
Enteral tubing misconnections, where feeding solutions are wrongly administered through intravenous (IV) tubing or other non-enteral systems, have been a concern for nearly thirty years. Most commonly occurring in intensive care settings, where patients have multiple types of tubing connections, an enteral tubing misconnection can result in catastrophic complications and possibly death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53580-nestle-health-science-launches-next-generation-spikeright-plus-pediatrics
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
